- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03800394
Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents
August 6, 2024 updated by: University of Florida
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
Tenofovir (TFV) disoproxil fumarate (TDF) plus emtricitabine (FTC) or lamivudine (3TC) is the preferred nucleoside backbone of first-line antiretroviral therapy (ART) for adolescents in sub-Saharan Africa.
In addition, TDF/FTC is recommended for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection in adolescents at substantial risk of acquisition of HIV infection, as well as for hepatitis B virus (HBV) treatment in those with HBV/HIV coinfection.
The efficacy TDF and FTC are dependent on intracellular concentrations of the active phosphate anabolites, called TFV diphosphate (TFV-DP) and FTC triphosphate (FTC-TP).
However, the intracellular pharmacokinetics of TFV-DP and FTC-TP to examine the adequacy of current dosages in African adolescents has not been previously studied.
Thus, examining the pharmacokinetics (PK) of these widely used antiretrovirals in African adolescents is important as ART outcomes remain poor and the recommended dosages of these drugs for children and adolescent were extrapolated from drug approval clinical trials in adult in the United States and Europe.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This study will evaluate the intracellular PK of TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents with and without TB coinfection.
As the clinical effects of TDF and FTC are related to the intracellular concentrations of the phosphate anabolites, called TFV-DP and FTC-TP, there is a need to understand the cellular pharmacology of TDF interactions in African HIV-infected adolescents with and without TB, as the study team cannot extrapolate from US patients not on antituberculosis (anti-TB) drugs.
This study will enroll HIV-infected adolescents aged 10 to 18 years old with and without TB coinfection who are already established on ART.
The study team hypothesize that younger age, adenosine triphosphate (ATP)-binding cassette subfamily C (ABCC) single nucleotide polymorphisms (SNPs) and anti-TB therapy may influence the intracellular TFV-DP and FTC-TP concentrations in adolescents.
Study Type
Observational
Enrollment (Actual)
52
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kumasi, Ghana
- Kwame Nkrumah University of Science and Technology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 19 years (Child, Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adolescents aged 10-19 years with HIV with or without TB co-infection.
Description
Inclusion Criteria:
- HIV-infected adolescents aged 10 to 19 years old who are stable on antiretroviral regimen containing TDF/FTC (300/200 mg daily) for at least 8 weeks.
Exclusion Criteria:
- Unable to obtain informed signed consent from parent(s) or legal guardian.
- Pregnant or breast feeding.
- Require therapy for other opportunistic infections other than tuberculosis (TB).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
HIV only
Adolescents aged 10-19 years with HIV infection
|
Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
|
|
HIV/TB
Adolescents aged 10-19 years with HIV and TB coinfection
|
Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average concentration (Cav) of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.
Time Frame: After at least 8 weeks of HIV therapy.
|
Mean and median Cav of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.
|
After at least 8 weeks of HIV therapy.
|
|
Area under the time-concentration curve 0-24 hours (AUC0-24h) of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.
Time Frame: After at least 8 weeks of HIV therapy.
|
Mean and median AUC0-24h of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.
|
After at least 8 weeks of HIV therapy.
|
|
Cav of TFV-DP and FTC-TP PK in HIV-infected adolescents with and without TB coinfection.
Time Frame: After at least 8 weeks of HIV therapy.
|
Geometric mean intracellular TFV-DP and FTC-TP Cav in adolescents with TB/HIV coinfection compared to those only HIV infection.
|
After at least 8 weeks of HIV therapy.
|
|
AUC0-24h of TFV-DP and FTC-TP PK in HIV-infected adolescents with and without TB coinfection.
Time Frame: After at least 8 weeks of HIV therapy.
|
Geometric mean of intracellular TFV-DP and FTC-TP AUC0-24h in adolescents with TB/HIV coinfection compared to those with only HIV infection.
|
After at least 8 weeks of HIV therapy.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of age on TFV-DP and FTC-TP Cav.
Time Frame: After at least 8 weeks of HIV therapy.
|
Geometric mean of intracellular TFV-DP and FTC-TP Cav in adolescents aged 10 - 14 years old compared to that in adolescents aged 15 - 19 years old.
|
After at least 8 weeks of HIV therapy.
|
|
Effect of age on TFV-DP and FTC-TP AUC0-24h .
Time Frame: After at least 8 weeks of HIV therapy.
|
Geometric mean of intracellular TFV-DP and FTC-TP AUC0-24h in adolescents aged 10 - 14 years old compared to that in adolescents aged 15 - 19 years old.
|
After at least 8 weeks of HIV therapy.
|
|
Intracellular TFV-DP and FTC-TP Cav in adolescents compared to that in historical adult controls.
Time Frame: After at least 8 weeks of HIV therapy.
|
Geometric mean of intracellular TFV-DP and FTC-TP Cav in Ghanaian HIV-infected adolescent compared to published values in adults treated with similar dosage.
|
After at least 8 weeks of HIV therapy.
|
|
Intracellular TFV-DP and FTC-TP AUC0-24h in adolescents compared to that in historical adult controls.
Time Frame: After at least 8 weeks of HIV therapy.
|
Geometric mean of intracellular TFV-DP and FTC-TP AUC0-24h in Ghanaian HIV-infected adolescent compared to published values in adults treated with similar dosage.
|
After at least 8 weeks of HIV therapy.
|
|
Relationship between Adenosine triphosphate (ATP)-binding cassette subfamily C, member 2 (ABCC2), member 4 (ABCC4) and member 10 (ABCC10) SNPs and TFV-DP and FTC-TP AUC0-24h.
Time Frame: After at least 8 weeks of HIV therapy.
|
Relationship between ABCC2, ABCC4 and ABCC10 SNPs and intracellular TFV-DP and FTC-TP AUC0-24h.
|
After at least 8 weeks of HIV therapy.
|
|
Prevalence and covariates of intracellular TFV-DP Cav < 95 fmol/106 cells in adolescents.
Time Frame: After at least 8 weeks of HIV therapy.
|
Proportion of Ghanaian adolescents and factors associated with intracellular TFV-DP average concentration < 95 fmol/106 cells.
|
After at least 8 weeks of HIV therapy.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Awewura Kwara, MD, University of Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 28, 2019
Primary Completion (Actual)
May 31, 2024
Study Completion (Actual)
July 31, 2024
Study Registration Dates
First Submitted
January 3, 2019
First Submitted That Met QC Criteria
January 8, 2019
First Posted (Actual)
January 11, 2019
Study Record Updates
Last Update Posted (Actual)
August 7, 2024
Last Update Submitted That Met QC Criteria
August 6, 2024
Last Verified
August 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Tuberculosis
- Acquired Immunodeficiency Syndrome
- Coinfection
Other Study ID Numbers
- IRB201801820 - PKAdol
- 2R01HD071779 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.